hemocord biotecnologia

What hemocord biotecnologia does

Hemocord Biotecnologia is a Brazilian for-profit biotechnology company founded in 2004 and headquartered in São Leopoldo, Brazil. The company operates a cell and tissue bank that processes perinatal stem-cell materials, serving the Brazilian market with cryopreservation and biological sample storage services. With 11-50 employees, Hemocord is a small-scale operator in the niche of perinatal stem-cell banking, a service typically contracted by expecting families or healthcare providers for the long-term storage of cord blood and related biological materials.

The company's underlying technology and service model centers on the collection, processing, and cryogenic storage of perinatal biological materials (cord blood, cord tissue, and related stem-cell sources). However, specific details on laboratory technology, processing protocols, proprietary features, or platform architecture are not disclosed in the available source data — the company's website (hemocord.com.br) returned only a loading/verification page during data collection, preventing direct confirmation of product specifications or technical differentiation.

Hemocord's business model is consistent with the standard cell-banking revenue mechanics: one-time processing fees at collection plus recurring annual or multi-year storage fees for cryopreserved samples. The company is privately held, with no disclosed funding rounds, ownership structure, or investor information available. No customer segments, pricing tiers, distribution channels, or partnership data were accessible in the input material, limiting deeper characterization of the go-to-market motion and revenue trajectory.

Name

hemocord biotecnologia

Website

https://hemocord.com.br

Company type

Private

Founded year

2004

Headcount range

11–50 employees

Short description

Hemocord Biotecnologia is a Brazilian private biotechnology company founded in 2004 that operates a cell and tissue bank processing perinatal stem-cell materials for cryogenic storage. The company serves the Brazilian market from its São Leopoldo headquarters with 11-50 employees.

Ownership category

akta.pro rank

Product category

Stem Cell Banking

NAICS

Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

• Stem cell banking
• Cell tissue banking
• Biotechnology services
• Perinatal stem cells
• Cord blood processing

Headquarters

HQ city

São Leopoldo

HQ country

Brazil

HQ region

Latin America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Core offering

Hemocord Biotecnologia operates a cell and tissue bank that processes perinatal stem-cell materials. Founded in 2004 and based in São Leopoldo, Brazil, the company provides biological sample processing and storage services for stem cells derived from perinatal sources such as umbilical cord blood and tissue.

Differentiator

Problem solved

Functional benefit

Products and services

• Perinatal Stem Cell Banking Processing and storage service for stem cells collected from perinatal sources (such as umbilical cord blood and cord tissue) intended for individual families and patients.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• CordVida: Brazilian private cord blood bank operating collection, processing, and cryostorage services across multiple Brazilian states. Directly comparable to Hemocord in service line, customer (expectant parents), and operating geography.
• Cell Preserve: Brazil-based family cord blood and tissue bank offering similar perinatal stem-cell storage services. Comparable in target market, business model, and service scope to Hemocord.
• Criovida: Brazilian cryopreservation and stem-cell bank that processes and stores cord blood and other biological samples. Overlaps directly with Hemocord on storage technology, customer segment, and country focus.

Broad incumbents

• Cryo-Cell International: U.S.-listed cord blood and menstrual stem-cell bank with multi-decade operating history. Comparable in core offering (private cord blood storage) and recurring-revenue storage model, though substantially larger and publicly traded.
• ViaCord (Revvity): U.S.-based private cord blood and cord tissue bank, now part of Revvity. Comparable in service offering, customer base (expectant parents), and cryostorage business model, with greater scale and parent-company backing.
• Cord Blood Registry (CBR) / California Cryobank Life Sciences: One of the largest private U.S. cord blood banks, offering collection, processing, and long-term storage comparable to Hemocord's core service, with substantially broader geographic reach and brand recognition.

Regional players

• Cells4Life: UK-based cord blood and tissue bank offering private storage across multiple jurisdictions. Comparable in service line and storage model to Hemocord, but operating in a different geographic market.
• Smart Cells International: UK-headquartered private cord blood stem-cell bank with international distribution. Comparable service offering and target customer, though geographically focused on UK and EMEA markets rather than Brazil.
• Future Health Biobank: European private stem-cell bank storing cord blood, cord tissue, and other biological samples. Directly comparable in storage services and customer profile, with primary geographic focus in the UK and Europe.

Emerging players

• StemCyte: Hybrid public-private cord blood bank operating across the U.S., India, and Taiwan with a therapeutic-development angle. Overlaps with Hemocord on cord blood storage and processing, with additional clinical-trial exposure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/hemocord

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about hemocord biotecnologia